Boehringer Ingelheim
For Healthcare Professionals
Prof-merlin-keyfact1.png
reduced risk of CV death
or kidney disease progression*1,2
Prof-merlin-keyfact2.png
reduced risk of CV death
or hospitalisation for heart failure†3,4
Prof-merlin-keyfact3.png
reduced risk of CV death‡5

Prof. Christoph Wanner - How do the EMPA-KIDNEY results add up to the existing strong scientific evidence of empagliflozin?

14/03/2024  |  Author: Boehringer Ingelheim

Document ID: PC-MY-103557

Prof Christoph Wanner’s take on EMPA-KIDNEY

PEKP||Prof. Christoph Wanner - What is a typical patient that may benefit from the EMPA-KIDNEY trial results?
PEKP||Prof. Christoph Wanner - How relevant is the broad patient population within EMPA-KIDNEY for a general practitioner's daily practice?
PEKP||Prof. Christoph Wanner - How do you interpret the importance of EMPA-KIDNEY results with regards to the treatment of patients with CKD?
PEKP||Prof. Christoph Wanner - How do you interpret the results of the primary outcome of EMPA-KIDNEY?
PEKP||Prof. Christoph Wanner - For you as a nephrologist in your daily practice, what is the most impactful outcome that was shown in the EMPA-KIDNEY¹ trial?
PEKP||Prof. Christoph Wanner - How does this early intervention impact the heart?
PEKP||Prof. Christoph Wanner - How do the outcomes of the EMPA-KIDNEY trial help patients suffering from kidney disease?
PEKP||Prof. Christoph Wanner - How important is early diagnosis and intervention when it comes to CKD?
PEKP||Prof. Christoph Wanner - How do the EMPA-KIDNEY results add up to the existing strong scientific evidence of empagliflozin?
PEKP||Prof. Christoph Wanner - What are the major challenges today with treating kidney disease?

RELATED CONTENT